The Zhitong Finance App learned that Cansino Biotech (06185) rose more than 9%. As of press release, it had risen 9.84% to HK$23.45, with a turnover of HK$41.775,800.

According to the news, on Wednesday EST, the US Centers for Disease Control and Prevention (CDC) reported that a farm worker in Michigan tested positive for bird flu. This is the second case of human infection with bird flu in the US, indicating that the H1N5 bird flu virus is raging in the US. Affected by this, many US vaccine stocks surged on Wednesday. In addition, Kong Fanyi, head of the Department of Infectious Diseases and chair professor at the Department of Internal Medicine at the University of Hong Kong Medical School said that Hong Kong is currently in the respiratory syncytial virus (RSV) epidemic season, and cases are expected to continue to rise. The peak infection period is generally from July to September. High-risk people over the age of 60 and diabetics are urged to get the RSV vaccine as soon as possible.

According to reports, in terms of research and pipeline, the marketing application for Cansino Biotech's 13-valent pneumonia-conjugate vaccine PCV13i has been accepted; the infant component 100 dTCP has completed phase III clinical enrollment; the adsorbed tetanus vaccine has initiated phase III clinical trials; the recombinant shingles vaccine (adenovirus vector) has initiated phase I clinical trials in Canada; and the recombinant polio vaccine has initiated phase I clinical trials in Australia. Additionally, the company and AstraZeneca have entered into a cooperative development agreement on mRNA vaccine development.